USP8P1: A Drug Target / Disease Biomarker (G100287272)

Target Name: USP8P1

NCBI ID: G100287272

USP8P1

Other Name(s): D84394.7 | USP8 pseudogene 1 | USP8P

USP8P1: A Drug Target / Disease Biomarker

USP8P1, also known as USP8-P1, is a protein that is expressed in various tissues of the body, including the brain, lungs, heart, and kidneys. It is a member of the Usp9 family of transmembrane proteins, which are involved in a variety of cellular processes, including cell signaling, protein transport, and intracellular signaling.

USP8P1 has been identified as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has also been associated with several adverse clinical events, including neurotoxicity and cardiotoxicity.

One of the key reasons why USP8P1 has been identified as a potential drug target is its role in several neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the progressive accumulation of neurofibrillary tangles, which are thought to contribute to the symptoms of these diseases.

Studies have shown that USP8P1 is involved in the development and progression of neurodegenerative diseases, and that its levels are often increased in the brains of individuals with these conditions. Additionally, several studies have shown that USP8P1 has been associated with the neurotoxicity and cardiotoxicity of several neurodegenerative drugs, which suggests that it may be an attractive target for new therapies.

Another potential drug target for USP8P1 is its role in the development and progression of certain autoimmune disorders, such as multiple sclerosis and rheumatoid arthritis. These conditions are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage.

Studies have shown that USP8P1 is involved in the development and progression of autoimmune disorders, and that its levels are often increased in individuals with these conditions. Additionally, several studies have shown that USP8P1 has been associated with the development of neurotoxicity in individuals with autoimmune disorders, which suggests that it may be an attractive target for new therapies.

In addition to its potential as a drug target, USP8P1 has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has been shown to be increased in several types of cancer, including breast, ovarian, and prostate cancer. Additionally, USP8P1 has been shown to be involved in the development and progression of neurodegenerative diseases, and has been associated with the development of several autoimmune disorders.

Overall, USP8P1 is a protein that has been identified as a potential drug target and biomarker for several diseases. Its involvement in these conditions makes it an attractive target for new therapies, and its potential as a drug target and biomarker makes it a promising area of research. Further studies are needed to fully understand its role in these conditions and to develop new treatments.

Protein Name: USP8 Pseudogene 1

The "USP8P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about USP8P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets